Sandoz To Pay $265M To Resolve Claims In Price-Fixing MDL

By Dan McKay · February 29, 2024, 6:09 PM EST

Swiss generic drug and biosimilar manufacturer Sandoz announced Thursday that two of its subsidiaries have reached a $265 million settlement with the direct purchasers of generic medications to resolve allegations of...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

August 05, 2016

Recent Articles By Dan

November 19, 2024
No 'Tin Hats': Fluoride Ruling Offers Options As RFK Eyes Ban
November 15, 2024
Teva Defends Mifepristone Antitrust Case Against Corcept
November 12, 2024
Wash. Ballot Win Gives States Blueprint For 'Age Wave' Care
November 06, 2024
Voters Pass Medicaid Tax In Calif., Support IVF Coverage In Ill.
November 05, 2024
Biotech, Pharma Cos. Eye Impact Of DOJ's Foreign Data Rule
October 31, 2024
Beverly Hills Agrees To Abortion-Rights Training In Settlement
October 29, 2024
4th Circ. Quizzes Drugmaker Challenging W.Va. Abortion Law
October 29, 2024
Beyond Abortion, 7 Ballot Questions Set To Shape Care
October 23, 2024
NC Justices Scrutinize Scope Of Liability Shield In COVID Law
October 22, 2024
Drug-Shortage List Under Scrutiny After FDA Reversal